Douglas L. Drysdale
Chief Executive Officer
Doug Drysdale has been the driving force behind over 100 pharmaceutical and biotech transactions. For almost 20 years, he has been applying his leadership skills and strategic vision to building and growing complex, multi-region businesses. Prior to coming to Norwich, Mr. Drysdale served as Vice President, Mergers and Acquisitions, for Actavis Group hf. He also served in a vice presidential capacity for the multinational Alpharma, Inc., where he was in charge of their department of Global Business Development. At Forest Laboratories, Mr. Drysdale was responsible for their global licensing initiatives. His entrepreneurial character was formed early on, as co-founder of Alkensa, Inc., a CNS development company where Mr. Drysdale served as Executive Vice President of Corporate Development. An ardent student of the biological sciences as well as the pharmaceutical industry throughout his life, Mr. Drysdale earned his degree in microbial and molecular biology from the University of East Anglia, UK.
Terry Novak is responsible for leading Norwich Pharmaceuticals’ commercial business organization. With more than 30 years of experience building successful pharmaceutical businesses, his executive management within contract development and manufacturing includes his prior position as President and Chief Commercial Officer for Patheon, as well as an earlier role as President for DSM Pharmaceuticals. Mr. Novak holds a B.S. in biology from Muhlenberg College.
Kristin Arnold, Ph.D
Vice President, Product Development & Technical Services
Kristin A. Arnold, Ph.D is Vice President Product Development and Technical Services. Dr. Arnold has 20 plus years of experience in product development with technical expertise in solid dosage formulations. Prior to joining Norwich, Dr. Arnold worked for organizations including URL Pharma as Sr. Vice President Product Development, Alpharma (formerly Faulding Pharmaceutical Company) as Sr. Director Research and Development, FMC Corporation, Ecogen, and Monsanto. Dr. Arnold has over twenty publications in scientific journals, holds four US patents, and has over ten patent publications.
Vice President, U.S. Quality
Theresa Lamanec leads quality control and quality assurance at the Norwich facility. Ms. Lamanec has more than 25 years of experience in Research, manufacturing, packaging, regulatory and quality for finished drug product and API. Prior to joining Norwich, she served as Executive Director, Quality Operations, for Watson Pharmaceuticals Inc. In this position, she achieved Class A customer service levels and assured effective quality and compliance systems. Ms. Lamanec is seasoned in multi-site regional operations and distribution, contract operations, start-ups, new product launches, R&D quality, regulatory filings and inspections. Prior to Watson, she worked for Merck & Co. Inc., starting as an R&D Process Development Chemist, and holding positions of increasing responsibility for more than 20 years, with work experience throughout Latin America, North America and Asia. Ms. Lamanec holds a MS degree in medicinal chemistry from the University of Kansas and a BA in chemistry from Marist College.
Vice President, Operations
Brian Reid is responsible for the leadership of the commercial operations at Norwich, to include production, supply chain, technical operations, health and safety and facilities. Prior to joining Norwich, Mr. Reid held senior operations roles with Pfizer and Wyeth Pharmaceuticals including site operations lead and international strategy and operational excellence deployment within Asia Pacific and Latin America. He has also held leadership roles within the area of corporate diversity and business continuity planning. Mr. Reid holds a BS in Engineering and Management and a MS in Engineering and Global Operations Management from Clarkson University.